Patient-Reported Outcomes

Measuring individual true change with PROMIS using IRT-based plausible values

**Aims** A primary advantage of IRT-based patient-reported outcome measures such as PROMIS short forms and computer-adaptive tests is that each estimate of the latent trait comes with a standard error. Such measurement error needs to be acknowledged, …

Are OMERACT recommendations followed in clinical trials on fibromyalgia? A systematic review of patient-reported outcomes and their measures

**Purpose** Patient-Reported Outcomes (PROs) and its measures (PROMs) are key to outcome assessment in Fibromyalgia (FM) trials. The aim of this review was to investigate which domains and instruments were assessed in recent FM trials and to compare …

Health State Utility differed systematically in breast cancer patients between the EORTC QLU-C10D and the PROMIS Preference Score (PROPr)

**Background** The EORTC QLU-C10D and the PROMIS Preference score (PROPr) are new health state utility (HSU) scores for Quality-adjusted life years (QALY) in cost-effectiveness analyses. Both are expected to measure HSU more comprehensively than …

Frequently Used Patient-Reported Outcome (PRO) Measures of General Physical Function Were Highly Correlated With a Multi-Task Performance Outcome (PerfO) Test Battery

**Objectives** This study aimed to determine the relationship between frequently used patient-reported outcome (PRO) measures and a multi-task performance outcome (PerfO) measure of general physical function (PF) and to examine the association of …

Real-world reference scores for EORTC QLQ-C30 and EORTC QLQ-BR23 in early breast cancer patients

**Purpose** To deliver patient-reported outcome (PRO) reference data for breast cancer and various other breast diseases to facilitate the interpretation of PRO scores during routine breast cancer treatment. **Methods** To determine reference …

PRO B: evaluating the effect of an alarm-based patient-reported outcome monitoring compared with usual care in metastatic breast cancer patients—study protocol for a randomised controlled trial

**Background** Despite the progress of research and treatment for breast cancer, still up to 30% of the patients afflicted will develop distant disease. Elongation of survival and maintaining the quality of life (QoL) become pivotal issues guiding …

New Publication: Building a Value-Based Care Infrastructure in Europe: The Health Outcomes Observatory

Our new study introducing the Health Outcomes Observatory (H2O), a multi-jurisdictional ecosystem to incorporate patient-reported and other health outcomes into health care decision-making across Europe, is out! Leaders at the European Union’s Innovative Medicines Initiative are developing a large-scale multi-stakeholder international ecosystem to incorporate patient-reported outcomes and measures to improve patient engagement and drive value.